Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166198 | 0.86 | ALOX15 (0.52) | CA1CA2CA7CA9KDM4E | |
| SCHEMBL29539686 | 0.86 | ALOX15 (0.52) | CA1CA2CA7CA9KDM4E | |
| SCHEMBL29061556 | 0.74 | CA1 (0.42) | CA1CA2CA7CA9KDM4E | |
| SCHEMBL12884761 | 0.73 | TDP1 (0.46) | CA1CA2CA7CA9KDM4E | |
| Phthalic Anhydride SCHEMBL11451509 | 0.73 | TDP1 (0.67) | KDM4ECYP1A2CYP2C19ALOX15TDP1 | |
| SCHEMBL23914740 | 0.72 | CA1 (0.44) | CA1CA2CA7CA9KDM4E | |
| SCHEMBL28456026 | 0.72 | CA1 (0.44) | CA1CA2CA7CA9KDM4E | |
| SCHEMBL2589012 | 0.72 | ALOX15 (0.33) | KDM4EALOX15TDP1TYMSALDH1A1 | |
| Phthalic Anhydride SCHEMBL9246027 | 0.72 | TDP1 (0.74) | KDM4ECYP1A2CYP2C19ALOX15TDP1 | |
| SCHEMBL6036681 | 0.72 | TDP2 (0.52) | CA1CA2CA7CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-4622177-A | 9-deoxy-9-isocyanato clavulante intermediates | BEECHAM GROUP P.L.C. (GB) | 1986-11-11 | — | — | US | claimed |
| EP-0104010-B1 | INTERMEDIATES FOR CLAVULANIC-ACID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1986-04-30 | — | — | EP | claimed |
| US-4473578-A | ACID, ESTER OR SALT DERIVATIVES OF MERCAPTO CARBAPENEMS | BEECHAM GROUP LIMITED (GB) | 1984-09-25 | — | — | US | claimed |
| US-4454069-A | Clavulanic acid salts and their preparation from the tertiary butyl amine salt | BEECHAM GROUP LIMITED (GB) | 1984-06-12 | — | — | US | claimed |
| EP-0104010-A1 | Intermediates for clavulanic-acid derivatives | BEECHAM GROUP PLC (GB) | 1984-03-28 | — | — | EP | claimed |
| US-4421760-A | β-Lactam antibiotic, its preparation and use | BEECHAM GROUP LIMITED (GB) | 1983-12-20 | — | — | US | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| WO-2023085402-A1 | PEPTIDE HAVING INHIBITORY ACTIVITY ON FORMATION OF LEUKOCYTE EXTRACELLULAR TRAPS | 平橋 淳一 | 2023-05-19 | — | — | WO | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-0044142-A1 | Process for the preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0044170-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0043197-A1 | Beta-Lactam antibiotic, its preparation and use | BEECHAM GROUP PLC (GB) | 1982-01-06 | — | — | EP | disclosed |
| EP-0028497-A1 | Beta-lactam antibiotics, their preparation and their use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
| EP-0026044-A1 | Amine salt of clavulanic acid, its preparation and use | BEECHAM GROUP PLC (GB) | 1981-04-01 | — | — | EP | disclosed |
| EP-0024832-A1 | Beta-lactam antibiotics, their preparation, pharmaceutical compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | CA1 2782/4885CA2 3468/4885CA7 1173/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | CA1 4312/4885CA2 4478/4885CA7 3203/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | CA1 4696/4885CA2 4306/4885CA7 4666/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | CA1 2404/4885CA2 3910/4885CA7 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.